Becton Dickinson and (NYSE:BDX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Becton Dickinson and (NYSE:BDX) issued its quarterly earnings results on Tuesday. The medical instruments supplier reported $3.08 earnings per share for the quarter, beating the consensus estimate of $3.05 by $0.03, Briefing.com reports. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. The firm had revenue of $4.35 billion during the quarter, compared to the consensus estimate of $4.37 billion. During the same period last year, the company earned $2.91 earnings per share. The company’s revenue was up 1.7% on a year-over-year basis. Becton Dickinson and updated its FY 2019 guidance to $11.65-11.75 EPS.

Becton Dickinson and stock opened at $239.65 on Wednesday. The company has a debt-to-equity ratio of 0.82, a current ratio of 0.96 and a quick ratio of 0.59. Becton Dickinson and has a one year low of $208.62 and a one year high of $265.87. The stock has a market capitalization of $67.08 billion, a PE ratio of 21.77, a PEG ratio of 1.84 and a beta of 1.11. The firm’s fifty day simple moving average is $250.87.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, September 6th. This represents a $3.08 annualized dividend and a dividend yield of 1.29%. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

In related news, EVP Betty D. Larson sold 1,700 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $224.97, for a total transaction of $382,449.00. Following the sale, the executive vice president now directly owns 11,493 shares of the company’s stock, valued at $2,585,580.21. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Samrat S. Khichi sold 16,085 shares of the stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $234.68, for a total value of $3,774,827.80. Following the sale, the executive vice president now directly owns 12,608 shares in the company, valued at $2,958,845.44. The disclosure for this sale can be found here. Insiders have sold 21,154 shares of company stock worth $4,955,775 over the last ninety days. 0.12% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in BDX. Ronna Sue Cohen boosted its position in Becton Dickinson and by 24,129.0% in the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock worth $5,734,000 after purchasing an additional 5,710,365 shares during the last quarter. Thoroughbred Financial Services LLC boosted its position in Becton Dickinson and by 25,302.2% in the second quarter. Thoroughbred Financial Services LLC now owns 990,940 shares of the medical instruments supplier’s stock worth $99,094,000 after purchasing an additional 987,039 shares during the last quarter. FMR LLC boosted its position in Becton Dickinson and by 5.0% in the first quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock worth $4,453,934,000 after purchasing an additional 842,590 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Becton Dickinson and by 10.4% in the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock worth $1,103,526,000 after purchasing an additional 416,459 shares during the last quarter. Finally, Intermede Investment Partners Ltd purchased a new position in Becton Dickinson and in the second quarter worth about $76,019,000. 84.85% of the stock is currently owned by institutional investors.

BDX has been the subject of several analyst reports. Morgan Stanley raised their price target on Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a report on Tuesday, July 16th. Piper Jaffray Companies reduced their price target on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a report on Tuesday. UBS Group reduced their price target on Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, May 10th. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a report on Monday, May 20th. Five equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $264.27.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: Momentum Indicators

Earnings History for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.